Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-lable, Multi-center, Active-controlled Phase 2 Study for Evaluating Efficacy and Safety of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering

NCT05936281 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05936281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05936281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-lable, Multi-center, Active-controlled Phase 2 Study for Evaluating Efficacy and Safety of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2023
Completion date
January 19, 2024
Enrollment
165 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gout, gout initiating urate-loweringurate-lowering therapy